Defence Therapeutics Inc. (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Montreal-based biotechnology company focused on precision oncology using its proprietary Accum® drug-delivery platform, has announced the payment of accrued interest on its convertible debentures through the issuance of 320,000 common shares. The company also disclosed receipt of a third settlement payment under its sharing agreement with Sorbie Bornholm LP. Both developments provide investors with an update on the company's capital management activities and ongoing financial arrangements.

Key Points

  • Defence Therapeutics Inc. (CSE: DTC, OTCQB: DTCFF, FSE: DTC) is a publicly traded biotechnology company listed on the Canadian Securities Exchange.
  • The company issued 320,000 common shares to satisfy $160,000 in accrued interest on $2,000,000 in convertible debentures bearing 8% per annum interest.
  • A third settlement of $190,670.42 was received from Sorbie Bornholm LP as of October 14, 2026, with 15 settlement payments remaining and 9,090,911 placement shares still held in escrow.
  • Investors may be watching the pace of remaining Sorbie Bornholm settlements and the impact of ongoing share issuances on dilution.

Convertible Debenture Interest Settled With 320,000 Common Shares

In accordance with the terms of convertible debentures originally dated September 15, 2025, Defence Therapeutics has issued 320,000 common shares to debenture holders to satisfy $160,000 in accrued and unpaid interest. The debentures carry a principal amount of $2,000,000 and bear interest at a rate of 8% per annum. The newly issued Interest Shares are subject to a statutory hold period of four months plus one day under applicable Canadian securities laws, meaning they cannot be freely traded on the open market until that period expires.

Third Sorbie Bornholm Settlement Received as Escrow Balance Continues

Defence Therapeutics confirmed it has received the third settlement payment of $190,670.42 under its sharing agreement with Sorbie Bornholm LP, dated March 6, 2026. The settlement, recorded as of October 14, 2026, was made against 606,060 placement shares released to Sorbie Bornholm LP. As of the announcement date, 9,090,911 placement shares remain held in escrow in connection with the sharing agreement. The company disclosed that 15 settlement payments remain outstanding under the arrangement, indicating the agreement is expected to continue generating periodic cash receipts.

Accum® Platform Underpins Defence Therapeutics' Biotechnology Focus

Defence Therapeutics continues to operate as a development-stage biotechnology company centred on its proprietary Accum® drug-delivery platform, which the company describes as targeting next-generation precision oncology therapeutics. The announcement does not include any clinical or operational updates related to the Accum® platform. Investors may be watching whether ongoing capital management activities, including the settlement of debenture interest in shares, affect the company's financial flexibility as it pursues its therapeutic development programme. The immediate share price impact was not clear from available public information.